SCHEMBL2852695

SCHEMBL2852695

CCc1cc(N2CCN(C(=O)OC(C)(C)C)CC2)c2nc(C=CC(=O)OC)ccc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 2/20 0.40
SKP1 P63208 2/20 0.40
SKP2 Q13309 2/20 0.40
BACE1 P56817 2/20 0.39
ACHE P22303 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
GPR119 Q8TDV5 1/20 0.37
MAP4K4 O95819 1/20 0.37
SLC2A1 P11166 1/20 0.37
NR1H2 P55055 1/20 0.37
MEN1 O00255 1/20 0.36
CYP2C19 P33261 1/20 0.36
KMT2A Q03164 1/20 0.36
SMARCA2 P51531 1/20 0.36
SMARCA4 P51532 1/20 0.36
PBRM1 Q86U86 1/20 0.36
PTPN11 Q06124 1/20 0.36
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2852692 1.00 CKS1B (0.40) CKS1BSKP1SKP2BACE1ACHE
SCHEMBL2854544 0.90 ACHE (0.45) CKS1BSKP1SKP2BACE1ACHE
SCHEMBL2854539 0.90 ACHE (0.45) CKS1BSKP1SKP2BACE1ACHE
SCHEMBL2850829 0.87 BACE1 (0.44) CKS1BSKP1SKP2BACE1ACHE
SCHEMBL2850831 0.87 BACE1 (0.44) CKS1BSKP1SKP2BACE1ACHE
SCHEMBL3913434 0.87 KIT (0.37) SMN1; SMN2LMNAMAPTMEN1KMT2A
SCHEMBL3909168 0.77 ADRA1A (0.37) SMN1; SMN2LMNAMAPTMEN1KMT2A
SCHEMBL3915607 0.75 KIT (0.38) BACE1SMN1; SMN2LMNAMAPTGPR119
SCHEMBL3908051 0.75 KIT (0.38) BACE1SMN1; SMN2LMNAMAPTGPR119
SCHEMBL2878173 0.74 KMT2A (0.49) CKS1BSKP1SKP2BACE1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2027108-B1 HISTAMINE RECEPTOR ANTAGONISTS COMPRISING AN AZEPIN CORE GLAXO GROUP LTD (GB) 2010-01-13 EP disclosed
US-20090181950-A1 Histamine Receptor Antagonists Comprising an Azepin Core GLAXO GROUP LIMITED (GB) 2009-07-16 US disclosed
EP-2027108-A1 HISTAMINE RECEPTOR ANTAGONISTS COMPRISING AN AZEPIN CORE Glaxo Group Limited (GB) 2009-02-25 EP disclosed
WO-2007135081-A1 HISTAMINE RECEPTOR ANTAGONISTS COMPRISING AN AZEPIN CORE GLAXO GROUP LIMITED (GB) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181950-A1 Histamine Receptor Antagonists Comprising an Azepin Core HRH2, HRH1, HRH4 CKS1B 3425/4885SKP1 2171/4885SKP2 2244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.